TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
EOLS

Evolus Inc

Healthcare · Drug Manufacturers - Specialty & Generic

8.00$ +0.3% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Evolus Inc (EOLS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 84 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EOLS
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
50 61 59 67 61 79 69 69 69 90 73 84 316
15 22 19 20 18 29 22 24 23 31 26 27 107
35 39 41 47 43 50 47 45 46 59 47 57 210
1.6 6.8 2.1 2.4 2.3 2.4 2.2 1.8 2.0 3.5 2.2 1.9 9.7
43 36 45 50 53 42 57 57 53 55 52 57 217
48 47 49 55 58 53 62 56 57 60 54 62 233
-13 -8.6 -8.9 -7.7 -15 -2.3 -15 -10 -12 -0.3 -6.9 -4.5 -23
3.8 4.1 4.7 4.7 4.8 4.6 4.4 7.2 4.1 4.0 4.0 4.2 16
-17 -12 -13 -11 -19 -6.4 -19 -17 -16 0.5 -10 -8.2 -34
0.0 0.1 0.0 0.0 0.1 0.4 0.1 0.1 0.2 0.4 0.3 -0.2 0.7
-17 -12 -13 -11 -19 -6.8 -19 -17 -16 0.1 -11 -8.1 -34
-12 -3.7 -6.8 -5.0 -13 0.6 -13 -7.8 -9.5 7.1 -3.8 -4.0 -10

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?